- Stock: In Stock
- Brand: Acme Laboratories Limited
- Product ID: Febuxostat
100% Secure Payment
Goustat 40 mg Tablet
Description
GOUSTAT (Febuxostat) is a potent non-purine, selective inhibitor of xanthine oxidase. GOUSTAT lowers serum uric acid levels by blocking xanthine oxidase, the enzyme responsible for uric acids production. Xanthine oxidase breaks down hypoxanthine (a natural-occurring purine derivative) to xanthine and then to uric acid.
Composition
Each film-coated tablet contains Febuxostat INN 40 mg.
Indications
GOUSTAT is indicated for the chronic management of hyperuricemia in patients with gout. However, asymptomatic hyperuricemia can not be treated with GOUSTAT.
Dosage and Administration
GOUSTAT is recommended at 40 mg or 80 mg once daily. The recommended starting dose of GOUSTAT is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg per dL after 2 weeks with 40 mg, GOUSTAT 80 mg is recommended.
GOUSTAT can be administered without regard to food or antacid use.
OR, AS DIRECTED BY THE PHYSICIAN.
Pediatric Use
Safety and effectiveness in children under 18 years of age have not been established.
Geriatric Use
No dose adjustment is necessary in elderly patients.
Hepatic Function Impairment
No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Cautions should be exercised in patients with severe hepatic impairment.
Renal Function Impairment
Dose adjustment is not required in patients with mild or moderate renal impairment.
Side effects
The most common side effects of Febuxostat include: Liver problems,
Nausea, Gout Flares, Arthralgia and Rash.
Contraindications
Febuxostat may cause increased plasma concentration of azathioprine, mercaptopurine, or theophylline leading to toxicity. It is not recommended for coadministration with these drugs.
Precautions
Gout Flare: An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including Febuxostat. If a gout flare occurs during treatment, Febuxostat need not be discontinued. Prophylactic therapy i.e., non-steroidal antiinflammatory drug (NSAID) or colchicine upon initiation of treatment may be beneficial for up to six months.
Cardiovascular Events: Monitor for signs and symptoms of MI and stroke & discuss with physician.
Liver Enzyme Elevation: Transaminase elevations have been observed in Febuxostat-treated patients. Monitor liver function tests periodically.
Use in Pregnancy and Lactation
Pregnancy Category C. There are no adequate and well- controlled studies in pregnant women. Febuxostat should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk.
Cautions should be exercised when Febuxostat is administered to a nursing woman.
Overdose
There is no evidence of dose-limiting toxicities in healthy subjects taking Febuxostat up to 300 mg daily for seven days. However,
Patients need to be managed by symptomatic and supportive care should there be an overdose.
Supply
Each box contains 2 x 10 tablets in blister strips.